Putaminal diffusion tensor imaging measures predict disease severity across human prion diseases

Therapeutic trials of disease-modifying agents in neurodegenerative disease typically require several hundred participants and long durations for clinical endpoints. Trials of this size are not feasible for prion diseases, rare dementia disorders associated with misfolding of prion protein. In this...

Descripción completa

Detalles Bibliográficos
Autores principales: Hyare, Harpreet, De Vita, Enrico, Porter, Marie-Claire, Simpson, Ivor, Ridgway, Gerard, Lowe, Jessica, Thompson, Andrew, Carswell, Chris, Ourselin, Sebastien, Modat, Marc, Dos Santos Canas, Liane, Caine, Diana, Fox, Zoe, Rudge, Peter, Collinge, John, Mead, Simon, Thornton, John S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7425333/
https://www.ncbi.nlm.nih.gov/pubmed/32954290
http://dx.doi.org/10.1093/braincomms/fcaa032

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7425333/
https://www.ncbi.nlm.nih.gov/pubmed/32954290
http://dx.doi.org/10.1093/braincomms/fcaa032

Ejemplares similares